Association between mutant IDHs and tumorigenesis in gliomas

Research output: Contribution to journalReview article

Abstract

To become immortalized, cells need to maintain the telomere length via the activation of telomerase or alternative lengthening of telomere. Mutations in IDH1/2 are strongly associated with the early stage of gliomagenesis. Previous work has shown that the accumulation of 2-HG, which is induced by mutant IDH1/2, inhibits α-KG-dependent deoxygenase and leads to genome-wide histone and DNA methylation alterations. These alterations are believed to contribute to tumorigenesis. H-Ras can transform human astrocytes with the inactivation of p53/pRb and expression of hTERT; however, mutant IDH1 can also transform cells. Moreover, mutant IDH1 can drive the immortalization and transformation of p53-/pRb-deficient astrocytes by reactivating telomerase and stabilizing telomeres in combination with increased histone lysine methylation and c-Myc/Max binding at the TERT promoter. It remains unclear whether mutant IDH1/2 acts only as the initial driver of gliomagenesis or it maintains transformed cells. Clinical studies are being performed to assess the use of mutant IDH1/2 inhibitors for treating gliomas.

Original languageEnglish
Pages (from-to)194-198
Number of pages5
JournalMedical Molecular Morphology
Volume51
Issue number4
DOIs
Publication statusPublished - 01-12-2018

Fingerprint

Glioma
Carcinogenesis
Telomerase
Telomere
Astrocytes
Histones
Telomere Homeostasis
DNA Methylation
Methylation
Lysine
Genome
Mutation
Clinical Studies

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology

Cite this

@article{cea8aefecaff4abcb7d9a35accfb02de,
title = "Association between mutant IDHs and tumorigenesis in gliomas",
abstract = "To become immortalized, cells need to maintain the telomere length via the activation of telomerase or alternative lengthening of telomere. Mutations in IDH1/2 are strongly associated with the early stage of gliomagenesis. Previous work has shown that the accumulation of 2-HG, which is induced by mutant IDH1/2, inhibits α-KG-dependent deoxygenase and leads to genome-wide histone and DNA methylation alterations. These alterations are believed to contribute to tumorigenesis. H-Ras can transform human astrocytes with the inactivation of p53/pRb and expression of hTERT; however, mutant IDH1 can also transform cells. Moreover, mutant IDH1 can drive the immortalization and transformation of p53-/pRb-deficient astrocytes by reactivating telomerase and stabilizing telomeres in combination with increased histone lysine methylation and c-Myc/Max binding at the TERT promoter. It remains unclear whether mutant IDH1/2 acts only as the initial driver of gliomagenesis or it maintains transformed cells. Clinical studies are being performed to assess the use of mutant IDH1/2 inhibitors for treating gliomas.",
author = "Shigeo Oba and Yuichi Hirose",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s00795-018-0189-8",
language = "English",
volume = "51",
pages = "194--198",
journal = "Medical Electron Microscopy",
issn = "0918-4287",
publisher = "Springer Japan",
number = "4",

}

Association between mutant IDHs and tumorigenesis in gliomas. / Oba, Shigeo; Hirose, Yuichi.

In: Medical Molecular Morphology, Vol. 51, No. 4, 01.12.2018, p. 194-198.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Association between mutant IDHs and tumorigenesis in gliomas

AU - Oba, Shigeo

AU - Hirose, Yuichi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - To become immortalized, cells need to maintain the telomere length via the activation of telomerase or alternative lengthening of telomere. Mutations in IDH1/2 are strongly associated with the early stage of gliomagenesis. Previous work has shown that the accumulation of 2-HG, which is induced by mutant IDH1/2, inhibits α-KG-dependent deoxygenase and leads to genome-wide histone and DNA methylation alterations. These alterations are believed to contribute to tumorigenesis. H-Ras can transform human astrocytes with the inactivation of p53/pRb and expression of hTERT; however, mutant IDH1 can also transform cells. Moreover, mutant IDH1 can drive the immortalization and transformation of p53-/pRb-deficient astrocytes by reactivating telomerase and stabilizing telomeres in combination with increased histone lysine methylation and c-Myc/Max binding at the TERT promoter. It remains unclear whether mutant IDH1/2 acts only as the initial driver of gliomagenesis or it maintains transformed cells. Clinical studies are being performed to assess the use of mutant IDH1/2 inhibitors for treating gliomas.

AB - To become immortalized, cells need to maintain the telomere length via the activation of telomerase or alternative lengthening of telomere. Mutations in IDH1/2 are strongly associated with the early stage of gliomagenesis. Previous work has shown that the accumulation of 2-HG, which is induced by mutant IDH1/2, inhibits α-KG-dependent deoxygenase and leads to genome-wide histone and DNA methylation alterations. These alterations are believed to contribute to tumorigenesis. H-Ras can transform human astrocytes with the inactivation of p53/pRb and expression of hTERT; however, mutant IDH1 can also transform cells. Moreover, mutant IDH1 can drive the immortalization and transformation of p53-/pRb-deficient astrocytes by reactivating telomerase and stabilizing telomeres in combination with increased histone lysine methylation and c-Myc/Max binding at the TERT promoter. It remains unclear whether mutant IDH1/2 acts only as the initial driver of gliomagenesis or it maintains transformed cells. Clinical studies are being performed to assess the use of mutant IDH1/2 inhibitors for treating gliomas.

UR - http://www.scopus.com/inward/record.url?scp=85045078709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045078709&partnerID=8YFLogxK

U2 - 10.1007/s00795-018-0189-8

DO - 10.1007/s00795-018-0189-8

M3 - Review article

C2 - 29633022

AN - SCOPUS:85045078709

VL - 51

SP - 194

EP - 198

JO - Medical Electron Microscopy

JF - Medical Electron Microscopy

SN - 0918-4287

IS - 4

ER -